IRD

Opus Genetics Inc

4.23

Jul 02 • 04:00PM ET +0.05 (1.20%)

Healthcare Biotechnology USA Small NASD

Peers: INCY BMRN KRYS KYMR NUVL RYTM AXSM MDGL VKTX NBIX

| Held by: VTI IWM IWO VXF IWC GSSC BSVO RSSL QQQS ITWO

Scroll to Statements

Index	RUT
Market Cap	349.25M
Enterprise Value	315.22M
Income	-106.93M
Sales	11.98M
Book/sh	-0.64
Cash/sh	0.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Nov 30, 2004

P/E	-
Forward P/E	-
PEG	-
P/S	29.15
P/B	-
P/C	5.82
P/FCF	-
EV/EBITDA	-
EV/Sales	26.31
Quick Ratio	7.13
Current Ratio	7.13
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.35
EPS next Y	-0.76
EPS next Q	-0.16
EPS this Y	-40.86%
EPS next Y	32.72%
EPS next 5Y	23.83%
EPS past 3/5Y	- 31.49%
Sales past 3/5Y	-29.11% -
EPS Y/Y TTM	30.28%
Sales Y/Y TTM	-12.22%
EPS Q/Q	-211.91%
Sales Q/Q	-50.64%
Earnings	May 12 BMO
EPS/Sales Surpr.	-458.87% -26.33%

Insider Own	18.93%
Insider Trans	-10.19%
Inst Own	50.54%
Inst Trans	1.31%
ROA	-186.04%
ROE	-449.36%
ROIC	-
Gross Margin	99.56%
Oper. Margin	-359.13%
Profit Margin	-892.36%
SMA20	4.79%
SMA50	-5.41%
SMA200	28.89%
Trades

Shs Outstand	71.40M
Shs Float	66.93M
Short Float	8.57%
Short Ratio	5.91
Short Interest	5.74M
52W High	5.81 -27.19%
52W Low	0.93 356.90%
Volatility	6.98% 7.27%
ATR (14)	0.28
RSI (14)	52.37
Beta	0.58
Rel Volume	0.87
Avg Volume	971.21K
Volume	847,547

Perf Week	13.71%
Perf Month	6.02%
Perf Quarter	-9.81%
Perf Half Y	116.92%
Perf YTD	110.45%
Perf Year	327.27%
Perf 3Y	-2.53%
Perf 5Y	-13.67%
Perf 10Y	-96.60%
Recom	1.00
Target Price	10.65
Prev Close	4.18
Price	4.23
Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-26	Initiated	RBC Capital Mkts	Outperform	$10
Jun-04-26	Initiated	Guggenheim	Buy	$16
May-21-26	Initiated	Leerink Partners	Outperform	$10
Apr-28-26	Initiated	Citizens	Mkt Perform	$12
Mar-30-26	Initiated	Cantor Fitzgerald	Overweight	$15
Mar-16-26	Initiated	Oppenheimer	Outperform	$10
Jan-20-26	Initiated	BTIG Research	Buy	$7
Dec-10-25	Initiated	B. Riley Securities	Buy	$9
Nov-25-25	Initiated	Piper Sandler	Overweight	$7
Oct-29-25	Initiated	Wedbush	Outperform	$8
Oct-16-25	Initiated	Chardan Capital Markets	Buy	$9
Apr-11-25	Initiated	Craig Hallum	Buy	$6
Nov-13-24	Resumed	H.C. Wainwright	Buy	$8

Show Previous Ratings

Jun-26-26 09:15AM	Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes (GlobeNewswire) +7.53%
Jun-16-26 04:05PM	Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases (GlobeNewswire)
Jun-02-26 07:00AM	Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts (GlobeNewswire)
May-28-26 04:01PM	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 08:00AM	Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
May-13-26 07:00AM	Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference (GlobeNewswire)
May-12-26 07:00AM	Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update (GlobeNewswire)
May-07-26 04:30PM	Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases (GlobeNewswire) -6.90%
07:00AM	Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study (GlobeNewswire)
May-04-26 04:30PM	Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program (GlobeNewswire)
Apr-27-26 08:00AM	Opus Genetics to Participate in Leading Medical Conferences in May 2026 (GlobeNewswire)
Apr-10-26 06:59AM	Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-06-26 07:00AM	Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital (GlobeNewswire)
Mar-24-26 07:00AM	Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (GlobeNewswire)
Mar-10-26 08:30AM	Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update (GlobeNewswire)
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +7.53%
Mar-03-26 08:00AM	Opus Genetics to Present at Upcoming Investor Conferences in March 2026 (GlobeNewswire)
Feb-27-26 10:10AM	Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting (GlobeNewswire) +15.88%
Feb-25-26 06:59AM	Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire)
Feb-13-26 07:30AM	Opus Genetics Announces $25 Million Private Placement (GlobeNewswire) +7.37%
Feb-02-26 08:00AM	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 (GlobeNewswire)
Jan-27-26 07:00AM	Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa (GlobeNewswire)
Jan-09-26 07:20AM	Opus Genetics highlights 2025 progress, upcoming 2026 catalysts (TipRanks)
Jan-08-26 07:00AM	Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts (GlobeNewswire) -5.21%
Dec-20-25 12:00PM	The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside (Barchart)
Dec-16-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.61%
Dec-11-25 07:00AM	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-09-25 07:00AM	Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease (GlobeNewswire)
Dec-02-25 04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
01:26AM	Loading…
Nov-29-25 01:26AM	Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With "Overweight" Rating and $7 PT (Insider Monkey)
Nov-20-25 08:00AM	Opus Genetics to Participate in Upcoming Investment Conferences (GlobeNewswire)
Nov-13-25 07:00AM	Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease (GlobeNewswire)
Nov-12-25 08:30AM	Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease (GlobeNewswire)
07:00AM	Opus Genetics Announces $23 Million Registered Direct Offering (GlobeNewswire)
Nov-05-25 10:00AM	Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:40AM	Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates (Zacks)
Nov-04-25 05:15PM	Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 08:00AM	Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness (GlobeNewswire) -6.96%
Oct-14-25 08:00AM	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-02-25 08:00AM	Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 (GlobeNewswire)
Oct-01-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Opus Genetics, Inc. (IRD) is a Great Choice (Zacks) +9.09%
Sep-30-25 07:00AM	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) (GlobeNewswire) -7.82%
Sep-16-25 03:42AM	Zacks.com featured highlights include Sally Beauty, Broadstone Net Lease and Opus Genetics (Zacks)
Sep-15-25 03:00PM	The Under $20 Breakout Trio Investors Shouldn't Ignore (Zacks)
Sep-12-25 08:00AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-25 08:00AM	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire)
Sep-03-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer (GlobeNewswire)
Aug-27-25 08:00AM	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September (GlobeNewswire)
Aug-18-25 08:00AM	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 (GlobeNewswire)
Aug-13-25 05:40PM	Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +7.27%
04:30PM	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-23-25 08:00AM	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-03-25 04:30PM	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-25 06:55AM	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire) +5.13%
Jun-23-25 08:00AM	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program (GlobeNewswire)
Jun-02-25 08:00AM	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions (GlobeNewswire) +9.60%
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-14-25 06:55PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 08:00AM	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May (GlobeNewswire)
May-08-25 09:25AM	Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 08:00AM	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate (GlobeNewswire)
May-05-25 08:00AM	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision (GlobeNewswire)
May-02-25 10:00AM	Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline (Zacks)
Apr-15-25 10:36AM	PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath (GlobeNewswire)
Apr-11-25 03:47PM	Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns (GlobeNewswire)
Apr-08-25 08:00AM	Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases (GlobeNewswire) -11.50%
Apr-07-25 08:00AM	Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress (GlobeNewswire)
Apr-02-25 08:00AM	Opus Genetics to Participate in Upcoming Investor Conference in April (GlobeNewswire)
Mar-31-25 08:20AM	Opus Genetics Announces Financial Results for Full Year 2024 (GlobeNewswire)
Mar-21-25 05:03PM	Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics (GlobeNewswire) +9.57% -8.73%
09:30AM	Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX (GlobeNewswire)
09:11AM	Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million (GlobeNewswire)
Mar-19-25 03:56PM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 08:00AM	Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting (GlobeNewswire)
Feb-26-25 08:00AM	Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs (GlobeNewswire)
Feb-18-25 07:30AM	Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program (GlobeNewswire)
Feb-07-25 09:15AM	Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. (GlobeNewswire) -5.74%
Dec-19-24 08:00AM	Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy (GlobeNewswire) +18.93%
Dec-03-24 08:00AM	Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 (GlobeNewswire) +5.22%
Nov-14-24 06:40AM	Opus Genetics reinstated with a Buy at H.C. Wainwright (TipRanks)
Nov-12-24 08:00AM	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire)
07:59AM	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 12:00PM	The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics (PR Newswire)
Oct-23-24 05:31PM	Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics (TipRanks) -12.03%
Oct-22-24 04:05PM	Ocuphire Pharma Announces Acquisition of Opus Genetics (GlobeNewswire)
Sep-30-24 08:00AM	Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology (GlobeNewswire)
Sep-05-24 08:43PM	UPDATE Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)
08:00AM	Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia (GlobeNewswire)

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

M.D.Dr. George Magrath M.B.A.

President & DirectorDr. Benjamin R. Yerxa Ph.D.

Chief Operating OfficerMr. Joseph K. Schachle MBA

Ph.D.Dr. Ashwath Jayagopal M.B.A.

M.B.A.Mr. Robert E. Gagnon CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foundation Fighting Blindness	Director	May 18 '26	Sale	4.35	1,700,000	7,395,000	3,792,171	May 20 07:29 PM
YERXA BENJAMIN R	President	Apr 23 '26	Sale	5.24	7,470	39,121	711,535	Apr 27 04:28 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Apr 23 '26	Sale	5.22	4,697	24,519	296,084	Apr 27 04:28 PM
Zaremba Rabourn Amy	Head of Fin. Quality Assurance	Apr 23 '26	Sale	5.20	1,641	8,540	188,671	Apr 27 04:27 PM
Magrath George	Chief Executive Officer	Apr 23 '26	Sale	5.22	9,511	49,647	1,741,344	Apr 27 04:27 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	Apr 23 '26	Sale	5.19	7,542	39,156	509,233	Apr 27 04:26 PM
Gagnon Robert E.	Chief Financial Officer	Apr 23 '26	Sale	5.18	7,842	40,658	592,158	Apr 27 04:26 PM
SCHACHLE JOSEPH K	Officer	Apr 23 '26	Proposed Sale	5.22	4,697	24,519		Apr 23 06:11 PM
YERXA BENJAMIN R	Officer	Apr 23 '26	Proposed Sale	5.24	7,470	39,121		Apr 23 05:55 PM
Magrath George	Officer	Apr 23 '26	Proposed Sale	13.39	9,511	127,327		Apr 23 04:36 PM
Gagnon Robert E.	Officer	Apr 23 '26	Proposed Sale	5.18	7,842	40,658		Apr 23 04:08 PM
Jayagopal Ashwath	Officer	Apr 23 '26	Proposed Sale	5.19	7,542	39,156		Apr 23 03:49 PM
SCHACHLE JOSEPH K	Chief Operating Officer	Mar 16 '26	Sale	5.25	3,719	19,525	300,781	Mar 18 04:12 PM
Zaremba Rabourn Amy	Head of Fin. Quality Assurance	Mar 16 '26	Sale	5.25	2,816	14,770	190,312	Mar 18 04:11 PM
Magrath George	Chief Executive Officer	Mar 16 '26	Sale	5.21	24,438	127,327	1,750,855	Mar 18 04:10 PM
Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	Mar 16 '26	Sale	5.12	3,719	19,046	516,775	Mar 18 04:09 PM
Magrath George	Officer	Mar 16 '26	Proposed Sale	5.21	24,438	127,327		Mar 16 04:54 PM
Gallagher Cam	Director	Dec 29 '25	Buy	1.97	83,000	163,419	83,000	Dec 31 04:33 PM
Gallagher Cam	Director	Dec 29 '25	Buy	1.98	81,000	160,275	1,891,430	Dec 31 04:33 PM
Foundation Fighting Blindness	Director	Dec 09 '25	Sale	2.15	4,000,000	8,600,000	5,492,171	Dec 11 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

IRD

Opus Genetics Inc

Upgrade your Finviz experience